GlassScriptPhysician profile
Sharon M Odell
NPI 1003867300
$3,176.70
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $1,047 · 2021: $720 · 2022: $440.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $604.65 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $358.63 | 2019-2022 | |
| Abbvie INC. | $225.13 | 2019-2022 | |
| Novo Nordisk INC | $210.32 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $186.39 | 2019-2022 | |
| Astellas Pharma US INC | $181.58 | 2019-2021 | |
| Amarin Pharma, INC. | $162.29 | 2019-2021 | |
| Lilly USA, LLC | $151.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $143.98 | 2020-2022 | |
| Pfizer INC. | $125.15 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.30 | 2019-2021 | |
| Allergan, INC. | $112.58 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $94.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $93.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $79.24 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $62.51 | 2022 | |
| Sunovion Pharmaceuticals INC. | $36.66 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.16 | 2021-2022 | |
| Aytu Biopharma, INC. | $34.07 | 2020 | |
| Eisai INC. | $33.01 | 2020-2021 | |
| Radius Health, INC. | $31.21 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.00 | 2022 | |
| Lundbeck LLC | $16.34 | 2020 | |
| Esperion Therapeutics, INC. | $16.00 | 2020 | |
| Abbott Laboratories | $15.49 | 2022 | |
| Medtronic Vascular, INC. | $14.61 | 2019 | |
| Gilead Sciences, INC. | $12.18 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Odell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.